

REFERENCES

1. **Adam R, Lucidi V, Karam V et al. (2005).** Liver transplantation in Europe: is there a room for improvement? *J Hepatol*; 42:44-40.
2. **Akabayashi A, Slingsby BT, Fujita M (2004).** The first donor death after living-related liver transplantation in Japan. *Transplantation*; 77: 634.
3. **Aqel BA, Scolapio JS, Dickson RC et al. (2005).** Contribution of ascites to impaired gastric function and nutritional intake in patients with cirrhosis and ascites. *Clin Gastroenterol Hepatol*; 3:1095-1100.
4. **Aranda-Michel J (2001).** Nutrition in hepatic failure and liver transplantation. *Curr Gastroenterol Rep*; 3:362-370.
5. **Bak T, Wachs M, Trotter J et al. (2001).** Adult – to adult living donor Liver transplantation using right – lobe grafts: results and lessons learned from a single – center experience. *Liver Transpl*, 7: 680-686.
6. **Baltz AC and Trotter JF (2003).** Living donor liver transplantation and hepatitis C. *Clin Liver Dis.*; 7:651-665
7. **Barcena MR, Cid GL, Lopez SP (2003).** Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine. *Transplant Proc.*; 35(5):1841-1843.
8. **Barle H, Nyberg B and Essen P (1997).** The synthesis rates of total liver Protein and plasma albumin determined simultaneously in vivo in humans. *Hepatology* 25: 154.
9. **Beavers KL, Sandler RS and Shrestha R (2002).** Donor morbidity Associated with right lobectomy for living donor liver transplantation to adult recipients: a systematic review. *Liver transplant*, 8: 110-17.
10. **Beckebaum S, Malago M, Dirsch O et al. (2003).** Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. *Clin Transplant*; 17(6):554-559.
11. **Ben Ari Z, Ashur Y, Daudi N et al. (2004).** Genotype prevalence, viral load

and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation. Clin Transplant.; 18(4):415-422.

12. **Berenguere M, Ferrell L, Watson J (2000).** HCV related fibrosis progression following liver transplantation: increase in recent years. J Hepatol; 32: 673-84.
13. **Bienze U, Gunther M, Neuhaus R et al. (2003).** Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology; 38(4):811-819.
14. **Bismuth H (1982).** Surgical anatomy and anatomical surgery of the liver World J Surg, 6(1): 3-9.
15. **Blumgart LH and William (2007).** Surgery of the liver, biliary tract & pancreas 4 th edition. Vol 2, P 430-530.
16. **Boillot O, Delafosse B, Mechet I et al. (2003).** Small for size partial liver Graft in an adult recipient, a new transplant technique. Lancet, 359: 406-7.
17. **Bold RJ and Goodnight JE Jr et al. (2004).** Hilar cholangio – carcinoma: Surgical and endoscopic approaches. Surg Clin North Am, 84: 525-42.
18. **Broering DC, Topp S, Schaefer U et al. (2002).** Split liver transplantation and risk to the adult recipient: analysis using matched pairs. J Am Coll Surg; 195:648-57.
19. **Borel JF (2002).** "History of the discovery of cyclosporin and of its early pharmacological development". Wien. Klin. Wochenschr. 114 (12): 433–7.
20. **Brown Jr RS, Russo MW, Lai M et al. (2003).** A survey of liver Transplantation from living adult donors in the United States. N Engl J Med, 348: 818 – 25.
21. **Brown RS (2005).** Hepatitis C and liver transplantation. Nature. 436:973-8.
22. **Bruix J, Sherman M, Liovert JM et al. (2000).** Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona – 2000 EASL Conference. European Association for the Study of the Liver. J

Hepatology, 35:421-430.

23. **Burak KW, Kremers WK, Batts KP et al. (2002).** Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. *Liver Transpl.*; 8:362-369.
24. **Buti M, Mas A, Prieto M et al. (2003).** A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIG) and lamivudine with long-term lamivudine plus HBIG in the prevention of hepatitis B virus recurrence after liver transplantation. *J Hepatology*; 38(6):811-817.
25. **Campos AC, Matias JE, Coelho JC (2002).** Nutritional aspects of liver transplantation. *Curr Opin Clin Nutr Metab Care*; 5:297-307.
26. **Carithers RL Jr (2000).** Liver transplantation. *Liver Transpl*; 122.
27. **Castells L, Vargas V, Allende H et al. (2005).** Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. *J Hepatology*; 43:53-9.
28. **Chalasani N, Manzarbeitia C, Ferenci P et al. (2005).** Pegasys Transplant Study Group. Peginterferon α 2a for hepatitis C after liver transplantation: two randomized, controlled trials. *Hepatology*. ; 41:289-298
29. **Charlton M (2001).** Hepatitis C infection in liver Transplantation, 1: 197-203.
30. **Chen CH, Chen Y, Chiang YJ et al. (2004).** Risks and quality-of-life changes in living kidney donors. *Transplant Proc*; 36: 1920-192.
31. **Chopra KB, Demetris AJ, Blakolmer K, et al. (2003).** Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. *Transplantation*. 2003; 76:1487-1491 conference on liver transplantation and hepatitis C. *Liver Transpl.* ; 9:S1-S9.
32. **Cosme M, Lewis T, Baburao K et al. (2005).** A multicenter evaluation of utility of chest computed tomography and Bone scans in liver transplant candidates with stages I and II hepatoma. *Annals of surgery*, 241 (4): 601-640.

33. **Couinaud C (1957).** Etudes anatomiques et chirurgicales. Paris, Masson
Quoted from: Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg; 6(1): 3-9.
34. **Crippin JS, McCashland T, Terrault N et al. (2002).** A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. ; 8:350-5.
35. **Dahmen U, Dirsch O, Li J et al. (2004).** Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation. ; 77(7):965-972.
36. **Dando T and Plosker G. (2003).** Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs; 63(20):2215-223.
37. **Davidson HI, Richardson R, Sutherland D et al. (1999).** Macronutrient preference, dietary intake, and substrate oxidation among stable cirrhotic patients. Hepatology; 29:1380-1386.
38. **Davis GL, Albright JE, Cook SF et al. (2003).** Projecting future complications of chronic hepatitis C in the United States. Liver Transpl; 9:331-8.
39. **Dewick P (2001).** Medicinal Natural Products. John Wiley & Sons, Ltd. 2nd ed. 2.Dienstag JL. Liver transplantation. In: Harrison's Principles of Internal Medicine 16th edition Vol II; 2005: 1873-80.
40. **Di Paolo D, Tisone G, Piccolo P et al. (2004).** Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver Transplantation. ; 77(8):1203-1208.
41. **Dodson SF, de Vera ME, Bonham CA et al. (2006).** Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl. ; 6(4):434-439.
42. **Dore GJ, Cooper DA, Pozniak AL et al. (2004).** Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naïve and -experienced patients coinfecting with HIV-1 and hepatitis B virus. J Infect Dis.; 189(7):1185-1192.

-
43. **El-Serag HB (2004).** Hepatocellular carcinoma: recent trends in the United States. *Gastroenterology*; 127:S27-34.
44. **El-zayadi A, Hanaa M, Eman MF et al. (2005).** Hepatocellular carcinoma in Egypt: A single center study over a decade. *World J Gastroenterology* ISSN; 11 (33): 5193-5198.
45. **Emond JC, RenZ JF, Ferrell LD et al. (1996).** Functional analysis of grafts from living donors: implications for the treatment of older recipients. *Ann Surg*; 244: 544-52.
46. **Erica and Allen BIO4161 (2002).** Human Anatomy & Physiology of the Liver: Anatomy, Physiology, Disease and Treatment Northeastern university December 7th, 2002.
47. **Estella M, Peter F, Whittington A et al. (2005).** Liver transplantation in children. *Paediatric Gastroenterology*, Vol 35, Suppl. I.
48. **Everson GT (2003).** Treatment of patients with hepatitis C virus on the waiting list. *Liver Transpl*; 9: 590-594.
49. **Everson GT, Trotter J, Forman L et al. (2005).** Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. *Hepatology*. ;42:255-62.
50. **Fan ST (2006).** Live donor liver transplantation in adults. *Transplantation*.; 82:723-32.
51. **Fasel JH, Selle D, Evertsz CJ et al. (1998).** Segmental anatomy of the Liver: poor correlation with CT. *Radiology*; 181(2): 443-8.
52. **Figueiredo FA, Dickson ER, Pasha TM et al. (2000).** Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. *Liver Transpl*; 6:575-581.
53. **Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. (2004).** One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. *Liver Transpl*; 10:1240-7.
54. **Fondfevila C, Ghobrial RM, Fuster J. (2003).** Biliary complications after
-

adult living donor liver transplantation. *Transplant Proc*; 35: 1902.

55. **Fontana RJ, Hann HW, Wright T et al. (2001).** A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. *Liver Transpl* ;7(6):504-510.
56. **Freeman R (2003).** Impact of MELD on GLTx for HCXC. Program and abstracts from the ASTS 3rd Annual Winter Symposium; January 24-26, Miami, Florida.
57. **Fulcher AS, Turner MA, Ham JM (2002).** Late biliary complications in right lobe living donor transplantation recipients: imaging findings and therapeutic interventions. *J Comput Assist Tomogr*; 26: 422- 427.
58. **Game EJ, McCaughan G, Strasser S et al. (2002).** Combination lamivudine plus low dose intramuscular hepatitis 'B immunoglobulin prevents recurrent hepatitis B and may eradicate residual graft infection. *Hepatology*, 36: 221A.
59. **Garden OJ and Bismuth H (1996).** Anatomy of the liver. In: Carter D, V Russell RCG, Pitt HA, Bismuth H, editors. *Rob and Smith's hepatobiliary and pancreatic surgery*. 5th ed. London: Chapman and Hall; p. 1-4.
60. **Georgopoulos P, Mowat C, McMillan DC et al. (2005).** Is portal hypertension associated with protein-losing enteropathy? *J Gastroenterol Hepatol*; 20:103-107.
61. **Ghobrial RM, Steadman R, Gornbein J et al. (2001).** A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. *Ann Surg*.; 234:384-393.
62. **Grieco A, Miele L, Pignaturo G et al. (2001).** Is celiac disease a confounding factor in the diagnosis of NASH? *Gut*; 49:596.
63. **Halpern SD, Ubel PA, Caplan AL et al. (2002).** Solid-organ transplantation in HIV-infected patients *N Eng J Med*; 347: 284-287.
64. **Han SH, Ofman J, Holt C et al. (2000).** An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation
-

compared with hepatitis B immune globulin monotherapy. *Liver Transpl.* ; 6(6):741-748.

65. **Harrison K, Brawn W, Fali J et al. (2005).** Principles of internal medicine Liver, 1873-1880.
66. **Harry DS and McIntyre N (1999).** Plasma lipids and lipoproteins. In bricher J, Benhamou J-P, McInterc N. Rizzetto J. eds. Oxford text book of Clinical Hepatology, 2nd ed. Oxford University Press, Oxford, p. 287.
67. **Hatao E, Kiuchi T, Tanaka T et at. (1997).** Hepatic reservation with histidie-tryptophan-Ketoglutarate solution in living-related and cadaveric liver transplantation. *Clin Sci*; 93: 81-8.
68. **Hay JE (2003).** Osteoporosis in liver diseases and after liver transplantation. *J Hepatol*; 38:856-865.
69. **Hay JE and Guichelaar MM.(2005).** Evaluation and management ofosteoporosis in liver disease. *Clin Liver Dis*; 9:747-766, viii.
70. **Hayashi M, Sakamoto S, Kiuchi T et al. (2002).** Current strategies for the Vse of suboptimal grafts in living donor liver transplantation. *Transplant Proc*; 34: 2567-8.
71. **Honkoop P and de Man RA. (2003).** Entecavir: a potent new antiviral drug for hepatitis B. *Expert Opin Investig Drugs* ;12(4):683-688 .
72. **Ito T, Kiuchi T, Egawa H et al. (2003).** Surgery-related morbidity in living donors of right lobe liver graft: lessons from the first 200 cases. *Transplantation*, 76: 158-63.
73. **John LR (2005).** Transplantation Philadelphia 3rd edition, P162-181.
74. **Kalayoglu M, Sollinger HW, Stratta RJ et al (1988).** Extended preservation of the liver for clinical transplantation. *Lancet*; 1: 617-9.
75. **Kalinina T, Iwanski A, Will H, Sterneck M.(2003).** Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. *Hepatology*. 389.9.

-
76. **Kamath PS (2001).** A model to predict survival in patients with end stage liver disease. *Hepatology*; 33.
77. **Karen F, Murray RL, Crithers Jr (2005).** AASLD Practice Guidelines: Evaluation of the Patient for Liver Transplantation. *Hepatology*, vol 41 No.6.
78. **Kim WR, Poterucha JJ, Kremers WK et al. (2004).** Outcome of liver transplantation for hepatitis B in the United States. *Liver Transpl*; 10(8):968.
79. **Krahn LE, DiMartini A (2005).** "Psychiatric and psychosocial aspects of liver transplantation". *Liver Transpl* 11 (10): 1157–68.
80. **Lashico T, Egawa H, Kasahara M et al. (2002).** Duct-to-duct biliary reconstruction in living donor liver transplantation utilizing right lobe grafts. *Ann Surg*; 236: 235-40.
81. **Launois B (1997).** Hepatectomy: the posterior intrahepatic approach. *Br J Surg*; 84: 291-2.
82. **Laurence S and Friedman MD (2008).** Liver, Biliary tract & Pancreas In: eds. *Current Medical Diagnosis and Treatment*; 556-609.
83. **Lee S, Hwang S, Park K et al. (2001).** An adult to adult living donor liver transplant using dual left lobe grafts. *Surgery*, 129: 647-50.
84. **Leslie WD, Bernstein CN, Leboff MS. (2003).** American Gastroenterological Association Clinical Practice Committee. AGA technical review on osteoporosis in hepatic Gastroenterology; 125:941-966.
85. **Lo CM (2003).** Complications and long-term outcome of living liver donors: a survey of 1,508 cases in five Asian centers. *Transplantation*; 75: S12-S15.
86. **Lo CM, Fan ST, Liu CL et al. (2006).** Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. *Liver Transpl*. 9(8):827-832.
87. **Lok AS and McMahon BJ (2001).** Chronic hepatitis B. *Hepatology*, 34: 225:1241.
-

-
88. **Lovert JM, Real MX, Planas BR et al. (2002).** Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. *Lancet*; 359: 1734-1739.
89. **LuNan, Boli, yong Zeng et al. (2006).** Modified technique for adult to adult living liver transplantation, transplantation hepatobiliary pancreatic Dis Int Vol 5, No 2, may 15.
90. **Luxon BA (2000).** Anatomy and physiology of the liver and biliary tree. In: Bacon BR, Di Bisceglie AM, editors. *Liver disease: diagnosis and treatment*. New York: Churchill Livingstone; p.3-15.
91. **Maluf D, Cotterell A, Clark B et al. (2005).** Hepatic angiosarcoma and V liver transplantation: case report and literature review. *Transplant Proc*; 37: 2195-2199.
92. **Manzarbeitia C, Reich DJ, Rothstein KD (2001).** Tacrolimus conversion improves hyperlipidaemic states in stable liver transplant recipients. *Liver Transpl*; 7: 93.
93. **Marcos A, Ham JM, Fisher RA et al. (2000).** Single center analysis of the first 40 adult-to-adult living donor liver transplants using the right lobe. *Liver Transpl*; 6: 296-301.
94. **Martinez OM, Rosen HR (2005).** "Basic concepts in transplant immunology". *Liver Transpl* 11 (4): 370–81. doi:10.1002/lt.20406.
95. **Marzano A, Salizzoni M, Debernardi-Venon W et al. (2005).** Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. *J Hepatol*; 34(6):903-910.
96. **McCaughan GW and Zekry A (2003).** Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. *Liver Transpl*; 9:S21-S275.
97. **McMinn RMH (1994).** Liver and biliary tract. In: McMinn RMH, editor. *Last's anatomy, regional and applied* 9th ed. Edinburgh: Churchill Livingstone, p. 342-51.
-

-
98. **Miller C, Florman S, Kim-Schluger L et al. (2004).** Live liver donor. *Liver Transpl*; 10: 1315-1319.
99. **Millonig G, Graziadci IW, Eichler D et al. (2005).** Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. *Liver Transpl*; 11:960-966.
100. **Mirabella S, Brunati A, Ricchiuti A et al. (2005).** New-onset diabetes after liver transplantation. *Transplant Proc*; 37:2636-2637.
101. **Mirilas P, Siatitsas Y and skandalakis JE (2002).** Benign anatomical mistakes: interior pulmonary ligament. *Ann Surg*; 68: 922-6.
102. **Munoz SJ (2002).** Use of hepatitis B core antibody-positive donors for liver transplantation. *Liver Transpl* ; 8(10 Suppl 1):S82-S87
103. **Multimer D (2006).** Liver Transplantation. *Medicine International, Liver Disorders Number*; 07(1):105-8.
104. **Nadalín S and Malagò M. (2007).** Current trends in live liver donation. *Transpl. Int.*; 20:312-30 1307.
105. **Nakamura T, Tanaka K, Kiuchi T et al. (2002).** Anatomical variations and surgical strategies in right lobe living donor liver transplantation: lessons from 120 cases. *Transplantation*, 73: 1896-903.
106. **Naoumov NV, Lopes AR, Burra P et al. (2006).** Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. *J Hepatol*; 34(6):888-894.
107. **Neff GW, Montalbano M, O'Brien CB et al. (2004).** Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. *Transplantation*. ;78:1303.
108. **Nishida T, Tsuji S, Tsujii M et al. (2006).** Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. *Am J Gastroenterol*; 101:70-75.
-

-
109. **Ojo AO, Held PJ, Port FK. (2003).** Chronic renal failure after transplantation of a non renal organ. *N Eng J Med*; 349:931.
110. **Park JS, Kim MH, Lee SK et al. (2003).** Efficacy of endoscopic and percutaneous treatments for biliary complications after cadaveric and living donor liver transplantation. *Gastrointest Endosc*; 57: 78- 85.
111. **Paulsen AW (1996).** Hepatic Anatomy, Physiology and Assessment of hepatic Function. In: Busuttil RW, Klintmalm GB, Eds. *transplantation of the Liver*, 1st Ed. WB Saunders Company, 43- 64.
112. **Pritchard DI (2005).** "Sourcing a chemical succession for cyclosporin from parasites and human pathogens". *Drug Discov. Today* 10 (10): 688–91.
113. **Pruett T (2002).** Indefinite passive immunization after liver transplantation for hepatitis B. *Liver Transpl* ;8(10 Suppl 1):S88-S89.
114. **Raia S, Nery JR and Mies S (1989).** Liver transplantation from liver donors. *Lancet*; 2(8661): 497.
115. **Ratych RE and Smith GW (1996).** Anatomy and physiology of the liver. In: Zuidema GO, editor. *Shackelford's Surgery of the Alimentary Tract*. 4th ed. Philadelphia: WB Saunders, p. 357-73.
116. **Reddy S, Zilvetti M, Brockmann J et al (2004).** "Liver transplantation from non-heart-beating donors: current status and future prospects". *Liver Transpl* 10 (10): 1223–32.
117. **Rerknimitr R, Sherman S, Fogel EL (2002).** Biliary tract complications after orthotopic liver transplantationwith choledocholedochostomy anastomosis. Endoscopic findings and results of therapy. *Gastrointes Endosc*; 55:224.
118. **Richards J, Gunson B, Johnson J et al. (2005).** Weight gain and obesity after liver transplantation. *Transpl Int*; 18:461-466.
119. **Richardson RA, Davidson HI, Hinds A et al. (1999).** Influence of the metabolic sequelae of livercirrhosis on nutritional intake. *Am J Clin Nutr*; 69:331-337.
-

-
120. Roayaie S, Schiano TD, Thung SN et al. (2003). Results of retransplantation for recurrent hepatitis C. *Hepatology*. ; 38:1428-36.
121. Robert L and Carithers JR (2000). Liver Transplantation guidelines; AASLD practice guidelines Vol. 6, No 1; pp 122-135.
122. Roberts L (2001). Clinical liver transplantation. *American Journal of transplantation*, I: 18-20.
123. Roche B, Feray C, Gigou M et al. (2003). HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immune prophylaxis. *Hepatology*; 38(1):86-95.
124. Rodriguez-Luna H, Khatib A, Sharma P et al. (2004). Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. *Transplantation*; 77:190-194.
125. Rogiers X, Malago M, Gawad K et al. (1996). One year experience with extended application and modified techniques of split liver transplantation. *Transplantation*; 6: 1059-61.
126. Russo MW, Galanko J, Beavers K et al. (2004). Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. *Liver Transplant*; 10:340-346.
127. Saab S, Chang AJ, Comulada S et al. (2003). Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. *Liver Transpl* ; 9(10):1053-1061.
128. Samuel D. (2004). Management of hepatitis B in liver transplantation patients. *Semin Liver Dis*; 24(Suppl 1):562.
129. Sanchez-Fueyo A, Rimola A, Grande L et al. (2003). Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. *Hepatology*. 31(2):496-501.
130. Sarasin FP, Majno PE, Llovet JM et al. (2001). Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. *Hepatology*, 33: 1073-1079.
-

-
131. **Schiff ER, Lai CL, Hadziyannis S et al. (2003).** Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. *Hepatology*; 38(6):1419-1427.
132. **Seehofer D, Rayes N, Berg T et al. (2000).** Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report. *Transplantation*; 69(8):1739-1742.
133. **Settmacher U, Theruvath T, Pascher A et al. (2004).** Living donor liver transplantation--European experiences. *Nephrol Dial Transplant*; 19 Suppl 4: iv16-21.
134. **Shakil AO, McGuire B, Crippin J et al. (2002).** A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. *Hepatology*; 36:1253-1258.
135. **Shimada M, Shiotani S, Ninomiya M et al. (2002).** Characteristics of liver grafts in living-donor adult liver transplantation. *Arch Surg*; 137: 074-1179.
136. **Stevens FM, McLoughlin RM (2005).** Is coeliac disease a potentially treatable cause of liver failure? *Eur J Gastroenterol Hepatol* 17:1015-1017.
137. **Strasberg SM, Belghiti J, Clavien PA et al. (2000).** The Brisbane 2000 terminology of liver anatomy and resections. Terminology Committee of the International Hepato-Pancreato-Biliary Association. *IJPB*; 2 (3): 333-9.
138. **Stravitz RT, Shiffman ML, Sanyal AJ et al. (2004).** Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. *Liver Transplant*; 10:850-858.
139. **Strong RW (2006).** Living-donor liver transplantation: an overview. *J Hepatobiliary Pancreat Surg*; 13:370-7.
140. **Sugawara Y, Makuuchi M (2004).** Advances in adult living donor liver transplantation: a review based on reports from the 10th anniversary of the adult-to-adult living donor liver transplantation meeting in Tokyo. *Liver Transpl*; 10:10.1016.
-

141. **Sullivan PG, Thompson M, Scheff SW (2000).** "Continuous infusion of cyclosporin A post injury significantly ameliorates cortical damage following traumatic brain injury". *Exp. Neurol.* 2 (3): 333-9.
142. **Tenney DJ, Levine SM, Rose RE et al. (2004).** Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. *Antimicrob Agents Chemother*; 48(9):3498-3507.
143. **Terrault NA (2002).** Treatment of recurrent hepatitis B infection in liver transplant recipients. *Liver Transpl* ;8(10 Suppl 1):S74-S81.
144. **Terrault NA and Vyas G. (2003).** Hepatitis B immune globulin preparations and use in liver transplantation. *Clin Liver Dis.*; 7(3):537-550.
145. **Thompson CA (2002).** Prodrug of tenofovir diphosphate approved for combination HIV therapy. *Am J Health Syst Pharm*; 59(1):18.
146. **Toniutto P, Fumo E, Caldato M et al. (2004).** Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. *Transplantation*; 77(3):472-473.
147. **Torpy JM (2006).** JAMA patient page Liver transplantation ; 295 (18): 2208.
148. **Toso C and Ris F Mentha G. (2002).** Potential impact of in situ liver splitting on the number of available grafts. *Transplantation*, 74:222-6.
149. **Tram TT, Nicholas NR, Fred FP et al. (2004).** Advances in liver transplantation. New strategies and current care expand access, enhance survival. *Postgrad Med*; 115:73-76, 79-85.
150. **Tuttle-Newhall JE, Collins BH, Desai DM et al (2005).** "The current status of living donor liver transplantation". *Curr Probl Surg* 42 (3): 144–83.
151. **Umeshita K, Fujiwara K, Kiyosawa K et al (2003).** "Operative morbidity of living liver donors in Japan". *Lancet* 362 (9385): 687–90.
152. **Van Bommel F, Wunsche T, Schurmann D et al. (2003).** Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. *Hepatology*; 36(2):507-508.

153. **Vargas HE, Donson FS and Rakela J (2002).** A concise update on the status of liver transplantation for hepatitis B: the challenges in 2002. *Liver Transplantation*. 8: 2-9.
154. **Villamil FG (2003).** Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. *J Hepatol* ;39(4):466-474.
155. **Villeneuve JP, Durantel D, Durantel S et al.(2003).** Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. *J Hepatol*.
156. **Vohra V (2006).** Liver transplantation in India. *Int Anesthesiol Clin*.;44:137-49.
157. **Wanless IR (1999).** Physioanatomic considerations. In: Schiff ER, Sorrell MF, Maddrey WC, editors. *Schiff's Diseases of the Liver*. 8th ed. Philadelphia: Lippincott-Raven, p. 3-37.
158. **Way LW (1994).** Liver L, in: way LW, editor. *Current surgical diagnosis and treatment* 10th ed. Norwalk: Appleton and Lange; p. 505-19.
159. **Wiederkehr JC, Pereira JC, Ekermann M et al. (2005).** Results of 132 hepatectomies for living donor liver transplantation: report of one death. *Transplant Proc*; 37: 1079-1080.
160. **Wiesner R, Edwards E, Freeman R (2003).** Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology*; 124:91-6.
161. **Wiesner RH, McDiarmid Sv, Kamath P et al. (2001).** Meld and PELD: application of survival models to liver allocation. *Liver transplantation*. 7: 567-580.
162. **Williams PL (1999).** Liver and biliary tract. In: Williams PL, Bannister LH, Berry MM et al. *Gray's anatomy: The anatomical basis of medicine and surgery*. 38th ed. inburgh: Churchill Livingstone, p. 1795-812.
163. **Wolters LM, Hansen BE, Niesters HG et al. (2002).** Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. *J Hepatol*; 37(1):137-144.
-

164. **Woodward RS, Schnit MA, Baty J et al. (2003).** Incidence and cost of new onset diabetes mellitus among US wait listed and transplanted allograft recipients. *Am J Transplant* ; 3: 590-8.
165. **Yao FY, Terrault NA, Freise C et al. (2005).** Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort; 1079-1080.
166. **Yersiz AM, Cameron I, Carmody MA et al., (2006).** Split liver transplantation, Elsevier; 602-603.